Participate in a glaucoma medication study
We invite your participation in a glaucoma medication treatment study beginning this December.
Participation by our patients gives them the opportunity to evaluate these medications, many times being compensated for their commitment to research. The most rewarding aspect of participation is the knowledge that you are able to enhance glaucoma treatment not only for yourself, but for your children and grandchildren as well. (Glaucoma is a hereditary disease.)
At this time we are screening patients for a new study that will begin in December 2008. This is a "comparison" study, meaning that we will compare the results of two already FDA approval formulas, Travatan Z and Xalatan. All patients will receive active medication throughout the study. It is a 3 month study requiring only 3 visits.
If you are currently using Xalatan only for IOP control and are interested in finding out more about this study, please call (502) 891-3563.
Dorothy Jett, COE
Administrator/Clinical Research Coordinator
Back to Top
“What are the latest advances in Glaucoma treatments?”
Two things: New medications and the newer laser procedures. The
new medications are easier to use. The latest laser procedures for
glaucoma are very effective and in many cases they can reduce or
eliminate the need for medications.
“What are the advantages to the glaucoma patient?”
These advances can reduce the requirement for medication thereby
saving the patient money. Newer laser procedures can make
difficult cases much easier to treat.
- Melvyn M. Koby, M.D.
“What's the most exciting advance in Cataract Surgery so
far?”
2.2 mm micro-incisions and the Multi-focal lens implants such as
RESTOR and CRYSTALENS
“What does that mean to the Cataract patient?”
Smaller incisions for cataract surgery means shorter healing time
and more rapid vision recovery for most patients. 2.2 mm microincisions
with new ultrasound equipment for cataract surgery may
also reduce the chance of rare but serious infections.
The new Multi-focal lens implants allow patients who are good
candidates the opportunity to enjoy good distance and reading
vision with minimal or no need for glasses following the cataract
procedure.
- R. Scott Hoffman, M.D.
“What is the most exciting advance in Cosmetic Eye Procedures
so far?”
The introduction of Botox® injections as well as very safe injectable
gels such as Juvederm™ and Restylane®, has provided very effective
tools to help patients who seek to smooth out wrinkles and
folds on the face instantly.
“What does that mean to the patient?”
Now our patients can have dramatic and immediate correction of
facial imperfections as well as lip augmentation without surgery.
The effect lasts for months.
The injections produce minimal discomfort and are performed in the
office. Affordability and reversibility of the effect are other major
advantages over surgical procedures. We offer free consultation to
those interested in using these very effective procedures to improve
their appearance.
- Albert Smolyar, M.D.
“What is the most exciting advance in Contact Lenses so far?”
Silicone Hydrogel lens material for contact lenses. This allows up to
8 times more oxygen through the lenses than previous lens
materials.
“What does that mean to the contact lens wearer?”
Throughout the course of the day you get significantly more oxygen
to the cornea often translating into a more comfortable wearing
experience with less end-of-the-day dryness and redness. Our
patients love them!
- Christopher Stroud, O.D.
Back to Top
 Dr. Melvyn M. Koby and Dr. David W. Karpare pleased to announce that Dr. R. Scott Hoffman, M.D. is now a full partner in the practice of Koby Karp Doctors Eye Institute. Dr. Hoffman will be taking a more active role in contributing to the continued development and growth of the practice.
“Dr. Koby and I have been greatly pleased with the valuable contributions that Dr. Hoffman has made to our practice over the past ten years,” said Dr. Karp recently. “ We are privileged to be associated with one of the most brilliant and dedicated ophthalmologists in this area.”
Dr. Hoffman joined Doctors Eye Institute in 1998 following fellowship training in the specialty of cornea and external diseases at the Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and Massachusetts Eye and Ear Infirmary. As a graduate of the University of Louisville and University of Kentucky School of Medicine, he completed residency training at the Texas Tech University Health Science Center. Dr. Hoffman’s specialty interests include management of corneal and anterior segment diseases of the eye, including corneal transplantation; small incision cataract and lens implant procedures and comprehensive ophthalmology. He also performs screening examinations and treats medical retina disorders such as diabetic retinopathy.
Congratulations to Dorothy Jett
30 year anniversary at Doctors Eye Institute
The Koby Karp doctors and staff recently threw a surprise party for our Practice Administrator, Dorothy Jett, to honor her for her 30 years of service to Doctors Eye Institute.
Dorothy began her career as receptionist to Drs. Melvyn Koby and David Karp in 1978. Over the years her experience has included work at every level and department in the organization. The last 12 years, her strengths have been focused in operations, human resources, ITS, accounting and marketing. Dorothy is affiliated with several ophthalmic associations including AAOE, JCAHPO, ASOA and ASCRS. She has also earned certifications as COT and COE.
In 2006 Ms. Jett was appointed to the National Board for the Certification of Ophthalmic Executives.
Dr. David W. Karp presented an award for distinguished service to Ms. Jett and commented that, "All of us are very proud of Dorothy’s exceptional achievements in her career. She has been invaluable to us in the growth and success of our practice."
Back to Top
New eyeglass lens has new Scotchgard™ Protection
 Essilor of America, Inc. has teamed with 3M Company to debut a state-of-the-art lens, Crizal Avancé™ with Scotchgard™ Protector, the Anti-Reflective lens that's made to stay clean. This exciting new generation of Crizal® lenses offers customers an unprecedented level of lens performance, cleanability and clarity.
 Crizal Avancé™ with Scotchgard™ Protector lenses offer patients the best available AR technology by combining the dramatically improved cleanability of the superhydrophobic topcoat with the industry-leading, antireflective, cleanability and durability benefits of Crizal Alizé™ with Clear Guard™ lenses along with the unmatched protection of Scotchgard™ Protector.
Learn more about these new lens innovations in our
Optical Department. New eyeglass lens haNew has
Scotchgard™ Protection
Back to Top
|
